查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371913

全球自动注射器市场，到 2030 年的预测：按类型、给药途径、治疗方法、分子类型、配销通路、最终用户和地区进行的全球分析

Auto-Injectors Market Forecasts to 2030 - Global Analysis By Type, Route of Administration, Therapy, Type of Molecule, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球自动注射器市场规模为 20.3 亿美元，预计到 2030 年将达到 79.4 亿美元，预测期内年复合成长率为 21.5%。

自动注射器是一种带有弹簧针头的注射器，预先装有药物。当注射器以滑动方式推入体内时，系统会启动并给药准确量的药物。自动注射器通常用于偏头痛患者自我给药肾上腺素以及医疗和紧急治疗。

根据美国国家健康访问调查 (NHIS)，近 52% 的美国成年人被诊断出患有至少一种慢性病，包括气喘、糖尿病和高血压。

慢性病增加

随着糖尿病、类风湿性关节炎和多发性硬化症等慢性疾病变得越来越普遍，自动注射器的需求也增加。自动注射器提供了一种安全可靠的方法来给药这些药物，通常会定期注射来治疗这些疾病。例如，国际糖尿病联盟（IDF）估计，2021年全球有5.37亿人罹患糖尿病，预计未来这一数字将迅速增加。糖尿病年度直接导致 150 万人死亡，其中大多数生活在低收入和中等收入国家。此外，由于已开发经济体和新兴经济体的预防性医疗保健的重要性日益增加，自动注射器市场统计数据预计将增加。

替代药物输送的潜力

传统上，注射药物是用注射器给药的，而且很痛苦。因此，其他给药方法，如口服、鼻腔和局部，越来越受到患者和医疗保健专业人员的关注。此外，技术的进步导致了无针注射器的发展，使得许多药物能够频繁地给药生长激素缺乏、类风湿性关节炎和糖尿病等疾病。因此，患有这些疾病的患者可能会对重复注射产生针头恐惧症，促使他们改用替代药物传递方法。

越来越多地转向家庭治疗

居家医疗正引起全世界的关注。这是由于医疗技术的进步、与医院治疗相比节省的大量资金以及患者偏好的变化。此外，自动注射器都开拓了技术进步，例如更容易操作和给药的视听提示、更好的帮助的连接性以及减少给药频率的大容量给药装置。 ，正在支持自动注射器的采用在家庭护理环境中，带来了市场机会。

法规挑战

严格的法规要求可能是一项重大挑战，尤其是在医疗保健和製药领域。法规变化、合规问题和冗长的核准流程可能会延迟我们产品的推出。因此，成本可能会增加并阻碍市场进入和成长。

COVID-19 的影响

儘管 COVID-19 的爆发扰乱了许多医疗保健业务，但自动注射器市场仍在经历强劲的收益成长。市场需求的进一步促进因素是 COVID-19 患者各种呼吸道併发症的发生率不断上升。自动注射器是一种自我给药的药物装置，其中包含用于治疗各种疾病的各种药物，包括类风湿性关节炎、糖尿病等。此外，自动注射器有助于定期给药，这在 COVID-19 大流行期间非常普及，当时医疗设施挤满了新冠肺炎 (COVID-19) 患者。

类风湿性关节炎领域预计在预测期内将是最大的。

预计类风湿性关节炎将在预测期内占据重要的市场占有率。类风湿性关节炎(RA) 是一种自体免疫疾病，当人体的免疫系统攻击关节、发炎并导致关节和周围组织肿胀和疼痛时，就会发生这种疾病。女性比男性更容易患关节炎，并且主要罹患老年人。例如，根据联合国《2020年世界人口预测》报告，目前全球65岁以上人口有7.27亿，预计到2050年这数字将增加一倍以上。随着老年人关节炎患病的上升，该市场预计在预测期内将扩大。

预计家庭护理领域在预测期内的年复合成长率最高。

预计家庭护理领域在预测期内将经历最高的年复合成长率。由于对家庭医疗服务的需求不断增长，自动注射器的使用预计会增加。许多药物，包括 DMARD、生物製药和疫苗，都可以使用这些设备进行给药。此外，居家医疗环境中对自动注射器的需求。

占比最高的地区

预计在预测期内，北美将占据一次性自动注射器的最大市场占有率。该地区的市场将受到技术先进产品的早期采用和产品核可以及慢性病患病患病上升等要素的推动。此外，由于技术进步、新参与企业的增加以及先进产品的快速采用，美国市场正在成长。因此，由于上述要素，北美地区预计将出现成长。

复合年复合成长率最高的地区

由于印度、中国、日本、新加坡和澳洲等国家糖尿病和食物过敏引起的过敏反应盛行率患病等要素，预计亚太地区将以最高的年复合成长率成长。糖尿病是许多亚洲国家的一个主要健康问题。因此，胰岛素自动注射器的使用增加，以帮助糖尿病患者有效管理病情。由于上述要素，亚太地区自动注射器市场具有巨大的成长潜力。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究来源
    • 主要研究来源
    • 二次研究来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球自动注射器市场：按类型

  • 一次性的
  • 可重复使用的
    • 预充式自动注射器
    • 空自动注射器

第6章全球自动注射器市场：依给药途径

  • 皮下的
  • 肌肉注射

第7章全球自动注射器市场：依治疗方法

  • 过敏反应
  • 气喘
  • 糖尿病
  • 荷尔蒙治疗
  • 偏头痛
  • 多发性硬化症
  • 肿瘤学
  • 类风湿性关节炎
  • 其他治疗方法

第8章全球汽车注射器市场：依分子类型

  • 单株抗体
  • 胜肽
  • 蛋白质
  • 低分子

第9章全球自动注射器市场：依配销通路

  • 医院药房
  • 零售药房
  • 网路药房

第10章全球自动注射器市场：依最终用户分类

  • 居家医疗环境
  • 医院/诊所
  • 门诊治疗

第11章全球自动注射器市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第12章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第13章公司简介

  • AbbVie Inc
  • Amgen Inc.
  • Antares Pharma
  • Bayer AG
  • Becton, Dickinson and Company
  • Biogen
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline plc
  • Halozyme Therapeutics Inc.
  • Johnson & Johnson
  • medmix Ltd.
  • Merck KGaA
  • Owen Mumford Ltd.
  • Pfizer Inc.
  • Recipharm AB
  • Teva Pharmaceutical
  • Ypsomed
Product Code: SMRC23970

According to Stratistics MRC, the Global Auto-Injectors Market is accounted for $2.03 billion in 2023 and is expected to reach $7.94 billion by 2030 growing at a CAGR of 21.5% during the forecast period. An auto-injector is a syringe with a needle that has been pre-charged with a dosage of drugs and is spring-charged. When a sliding motion is used to press the device into the body, the system activates and delivers a precise dosage of a medication. The self-administration of epinephrine by migraineurs or for medical and emergency treatments is frequently done with the aid of auto-injectors.

According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The demand for auto-injectors has also increased as chronic diseases like diabetes, rheumatoid arthritis, and multiple sclerosis are becoming more common. Auto-injectors provide a secure and reliable way to administer these medications, which are frequently injected regularly to treat these conditions. For instance, The International Diabetes Federation (IDF) estimates that 537 million people worldwide had diabetes in 2021, and that number is expected to rise sharply in the years to come. Since the majority live in low- and middle-income countries, diabetes directly causes 1.5 million deaths annually. Moreover, market statistics for auto-injectors will increase due to the rising significance of preventive care in both developed and developing economies.

Restraint:

Availability of alternative modes of drug delivery

Traditionally, injectable medications have been delivered with a syringe and are painful to receive. This is why other administration methods like oral, nasal, and topical routes are gaining more attention from both patients and healthcare professionals. Additionally, owing to technological developments, needle-free injectors have been created, and a lot of drugs are administered frequently for conditions like growth hormone deficiency, rheumatoid arthritis, and diabetes, among others. As a result, patients with these conditions may develop needle phobia as a result of repeated injections, which would encourage them to switch to alternative drug delivery methods.

Opportunity:

Rising shift of therapy to home settings

Home care settings are receiving more attention worldwide. This is supported by improvements in medical technology, significant financial savings over hospital-based treatments, and changing patient preferences. Additionally, the development of auto-injectors with technological advancements like audio-visual cues for easy handling and administration, connectivity for better assistance, and large dose and volume devices for less frequent drug administration are all supporting the adoption of auto-injectors in home care settings, which consequently offers opportunities in the market.

Threat:

Regulatory challenges

Stringent regulatory requirements, especially in the healthcare and pharmaceutical sectors, can pose significant challenges. Changes in regulations, compliance issues, and lengthy approval processes can delay product launches. As a result, it increases costs, which might impede market entry and growth.

COVID-19 Impact:

The COVID-19 outbreak has interfered with a number of healthcare operations, but the auto-injector market is still experiencing strong revenue growth. An additional driver of market demand is the rising incidence rate of various respiratory complications among COVID-19 patients. Auto-injectors are self-administration drug devices that contain a range of medications for the treatment of various illnesses, including rheumatoid arthritis, diabetes, and others. Additionally, auto-injectors aid in the administration of a regular dose of medication, which became very popular during the COVID-19 pandemic when healthcare facilities were overrun with COVID patients.

The rheumatoid arthritis segment is expected to be the largest during the forecast period

Over the forecast period, rheumatoid arthritis is anticipated to hold a sizable market share. An autoimmune condition called rheumatoid arthritis (RA) occurs when the body's immune system attacks the joints, inflaming the synovium and resulting in swelling and pain in the joints and the surrounding tissues. Women are more likely to have arthritis than men, and it primarily affects the elderly. For instance, According to the United Nations World Population Prospects 2020 report, there are currently 727 million people in the world who are 65 or older, and by the year 2050, this number is projected to more than double. As the prevalence of arthritis among the elderly population rises, this market segment will expand over the forecast period.

The homecare settings segment is expected to have the highest CAGR during the forecast period

During the anticipated timeframe, the segment for homecare settings is predicted to have the highest CAGR. The use of auto-injectors is anticipated to rise in response to the rising demand for healthcare services provided at home. Numerous medications, including DMARDs, biologics, and vaccines, can be administered using these devices. Moreover, the demand for auto-injectors in homecare settings will therefore be driven by the growing sophistication of healthcare infrastructure and accessibility, which is assisting in the market's expansion.

Region with largest share:

Throughout the forecast period, North America is anticipated to account for the largest market share for disposable auto-injectors. The market in the region is boosted by factors like early adoption of technologically advanced products and product approvals, as well as an increase in the prevalence of chronic diseases. In addition, the United States market is growing as a result of rising technological advancements, increased entry of new players, and quick adoption of advanced products. The North American region is therefore anticipated to experience growth as a result of the aforementioned factors.

Region with highest CAGR:

Due to factors like the rising prevalence of diabetes and anaphylaxis brought on by food allergies in nations like India, China, Japan, Singapore, and Australia, Asia Pacific is predicted to grow at the highest CAGR. In numerous Asian nations, diabetes is a major health concern. As a result, the use of insulin auto-injectors has increased to assist people with diabetes in effectively managing their condition. Due to the aforementioned factors, the Asia-Pacific region offers significant potential for growth in the auto-injector market.

Key players in the market:

Some of the key players in Auto-Injectors Market include: AbbVie Inc, Amgen Inc., Antares Pharma, Bayer AG, Becton, Dickinson and Company, Biogen, Eli Lilly and Company, F. Hoffmann La Roche Ltd., GlaxoSmithKline plc, Halozyme Therapeutics Inc., Johnson & Johnson, medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc., Recipharm AB, Teva Pharmaceutical and Ypsomed.

Key Developments:

In October 2023, AbbVie announced that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's Disease (PD). Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction that is believed to be a major contributing factor to Parkinson's disease pathogenesis and progression.

In October 2023, Amgen announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

Types Covered:

  • Disposable
  • Reusable

Route of Administration Covered:

  • Subcutaneous
  • Intramuscular

Therapies Covered:

  • Anaphylaxis
  • Asthma
  • Diabetes
  • Hormone Therapy
  • Migraine
  • Multiple Sclerosis
  • Oncology
  • Rheumatoid Arthritis
  • Other Therapies

Type of Molecules Covered:

  • Monoclonal Antibody
  • Peptide
  • Protein
  • Small Molecule

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Home Care Settings
  • Hospitals & Clinics
  • Ambulatory Care Settings

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Auto-Injectors Market, By Type

  • 5.1 Introduction
  • 5.2 Disposable
  • 5.3 Reusable
    • 5.3.1 Prefilled Auto-injectors
    • 5.3.2 Empty Auto-injectors

6 Global Auto-Injectors Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Subcutaneous
  • 6.3 Intramuscular

7 Global Auto-Injectors Market, By Therapy

  • 7.1 Introduction
  • 7.2 Anaphylaxis
  • 7.3 Asthma
  • 7.4 Diabetes
  • 7.5 Hormone Therapy
  • 7.6 Migraine
  • 7.7 Multiple Sclerosis
  • 7.8 Oncology
  • 7.9 Rheumatoid Arthritis
  • 7.10 Other Therapies

8 Global Auto-Injectors Market, By Type of Molecule

  • 8.1 Introduction
  • 8.2 Monoclonal Antibody
  • 8.3 Peptide
  • 8.4 Protein
  • 8.5 Small Molecule

9 Global Auto-Injectors Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Auto-Injectors Market, By End User

  • 10.1 Introduction
  • 10.2 Home Care Settings
  • 10.3 Hospitals & Clinics
  • 10.4 Ambulatory Care Settings

11 Global Auto-Injectors Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AbbVie Inc
  • 13.2 Amgen Inc.
  • 13.3 Antares Pharma
  • 13.4 Bayer AG
  • 13.5 Becton, Dickinson and Company
  • 13.6 Biogen
  • 13.7 Eli Lilly and Company
  • 13.8 F. Hoffmann La Roche Ltd.
  • 13.9 GlaxoSmithKline plc
  • 13.10 Halozyme Therapeutics Inc.
  • 13.11 Johnson & Johnson
  • 13.12 medmix Ltd.
  • 13.13 Merck KGaA
  • 13.14 Owen Mumford Ltd.
  • 13.15 Pfizer Inc.
  • 13.16 Recipharm AB
  • 13.17 Teva Pharmaceutical
  • 13.18 Ypsomed

List of Tables

  • Table 1 Global Auto-Injectors Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Auto-Injectors Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Auto-Injectors Market Outlook, By Disposable (2021-2030) ($MN)
  • Table 4 Global Auto-Injectors Market Outlook, By Reusable (2021-2030) ($MN)
  • Table 5 Global Auto-Injectors Market Outlook, By Prefilled Auto-injectors (2021-2030) ($MN)
  • Table 6 Global Auto-Injectors Market Outlook, By Empty Auto-injectors (2021-2030) ($MN)
  • Table 7 Global Auto-Injectors Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 8 Global Auto-Injectors Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 9 Global Auto-Injectors Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 10 Global Auto-Injectors Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 11 Global Auto-Injectors Market Outlook, By Anaphylaxis (2021-2030) ($MN)
  • Table 12 Global Auto-Injectors Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 13 Global Auto-Injectors Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 14 Global Auto-Injectors Market Outlook, By Hormone Therapy (2021-2030) ($MN)
  • Table 15 Global Auto-Injectors Market Outlook, By Migraine (2021-2030) ($MN)
  • Table 16 Global Auto-Injectors Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 17 Global Auto-Injectors Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 18 Global Auto-Injectors Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 19 Global Auto-Injectors Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 20 Global Auto-Injectors Market Outlook, By Type of Molecule (2021-2030) ($MN)
  • Table 21 Global Auto-Injectors Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 22 Global Auto-Injectors Market Outlook, By Peptide (2021-2030) ($MN)
  • Table 23 Global Auto-Injectors Market Outlook, By Protein (2021-2030) ($MN)
  • Table 24 Global Auto-Injectors Market Outlook, By Small Molecule (2021-2030) ($MN)
  • Table 25 Global Auto-Injectors Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 Global Auto-Injectors Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 27 Global Auto-Injectors Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 28 Global Auto-Injectors Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 29 Global Auto-Injectors Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Auto-Injectors Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 31 Global Auto-Injectors Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 32 Global Auto-Injectors Market Outlook, By Ambulatory Care Settings (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.